--- schema_version: "secwatch.filing_event.v1" accession: "0001683168-24-001917" form_type: "8-K" ticker: "BRGX" cik: "0001593184" company_name: "BIOREGENX, INC." filed_at: "2024-04-01T23:59:59+00:00" generated_at: "2026-06-04T04:40:02.188957+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.9 calibrated_materiality_score: 0.9 confidence: "high" source: SEC EDGAR --- # BioRegenx completes reverse merger with Findit; new board, name change effective March 8, 2024 ## Summary - BioRegenx merged into Findit (OTC Pink: FDIT); surviving entity renamed BioRegenx, Inc. - Former BioRegenx holders received 851,977,296 common + 3,800 Series A preferred shares, representing 90% voting control. - Prior shareholders retired 98.47% voting control preferred shares and 172,197,602 common shares. - New officers appointed: William Resides CEO/interim CFO; board expanded to 7 directors. - Authorized common stock increased to 1.5B shares; press release notes GlycoCheck device ($22k-$32k system) and DocSun 40% revenue share, $10/vehicle license fee. ## SEC filing metadata - accession: 0001683168-24-001917 - form_type: 8-K - ticker: BRGX - cik: 0001593184 - company_name: BIOREGENX, INC. - filed_at: 2024-04-01T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.9 - calibrated_materiality_score: 0.9 - confidence: high - sec_items: 2.01, 3.02, 5.01, 5.02, 5.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001683168-24-001917 - JSON: https://secwatch.observer/filing/0001683168-24-001917.json - Plain text: https://secwatch.observer/filing/0001683168-24-001917.txt ## Key facts - Executive change Sherri Adams was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Gary Hennerberg was appointed as Secretary at BIOREGENX, INC.. - Action: appointed - Role: Secretary source text: the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Jody Walker was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Gary Hennerberg was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Robert Doran was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Raymond Firth resigned as director at BIOREGENX, INC.. - Action: resigned - Role: director source text: Effective March 8, 2024, Raymond Firth resigned as a director of the Registrant evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change William Resides was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Sherri Adams was appointed as Chief Operating Officer at BIOREGENX, INC.. - Action: appointed - Role: Chief Operating Officer source text: the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Robert Doran was appointed as Executive Vice President at BIOREGENX, INC.. - Action: appointed - Role: Executive Vice President source text: the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Suzanne Bird was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Thomas Powers resigned as other_named_officer at BIOREGENX, INC.. - Action: resigned source text: Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Gary Kiss was appointed as director at BIOREGENX, INC.. - Action: appointed - Role: director source text: the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change Raymond Firth resigned as other_named_officer at BIOREGENX, INC.. - Action: resigned source text: Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Executive change William Resides was appointed as Chief Executive Officer, Interim Financial Officer at BIOREGENX, INC.. - Action: appointed - Role: Chief Executive Officer, Interim Financial Officer source text: the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Governance Changes BIOREGENX, INC.: Company name changed to BioRegenx, Inc (effective 2024-03-08). - Change: charter amendment - Effective: 2024-03-08 source text: Additionally, the name of the Registrant was changed to BioRegenx, Inc. evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Governance Changes BIOREGENX, INC.: Filed Certificate of Designation to cure 2013 creation of Series A preferred shares (effective 2024-03-14). - Change: charter amendment - Effective: 2024-03-14 source text: Effective March 14, 2024, the Registrant filed a Certificate of Designation (and subsequently, a Certificate of Correction) curing the 2013 creation of the Series A preferred shares and ratifying the issuances of 5,000,000 Series A preferred shares in 2013 evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - Governance Changes BIOREGENX, INC.: Increased authorized common stock to 1.5 billion shares (effective 2024-03-08). - Change: charter amendment - Effective: 2024-03-08 source text: Effective March 8, 2024, the Registrant filed an Amendment to the Articles of Incorporation which increased the authorized common stock to One Billion Five Hundred Thousand (1,500,000,000) common shares. evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm - M&A Transactions BIOREGENX, INC. underwent a change of control involving BioRegenx, Inc. (closed 2024-03-08). - Action: change of control - Counterparty: BioRegenx, Inc. - Closing: 2024-03-08 source text: The Registrant filed Articles of Merger effective March 8, 2024 with the state of Nevada. Pursuant to the Articles of Merger, BioRegenx, Inc, a Nevada corporation was merged into the Registrant with the Registrant being the surviving company. evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.